Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Alessia Bignucolo, Lucia Scarabel, Giuseppe Toffoli, Erika Cecchin & Elena De Mattia. (2022) Predicting drug response and toxicity in metastatic colorectal cancer: the role of germline markers. Expert Review of Clinical Pharmacology 15:6, pages 689-713.
Read now
Read now
Mohammad Jamshidi, Somayeh Mohammadi Pour & Mohammad-Reza Mahmoudian-Sani. (2020) Single Nucleotide Variants Associated with Colorectal Cancer Among Iranian Patients: A Narrative Review. Pharmacogenomics and Personalized Medicine 13, pages 167-180.
Read now
Read now
Articles from other publishers (27)
Kavita Trimal, Tejas Shah, Kalpana Joshi & Ghazala Mulla. (2019) Association of EGF A61G polymorphism and EGF expression with type 2 diabetes mellitus in Indian population. Gene Reports 15, pages 100384.
Crossref
Crossref
Xiaoying Zhu, Yan Shen & Qigui Xie. (2019) The association between EGF A61G polymorphism and risk of colorectal cancer in a Chinese population: a case-control study. Bioscience Reports 39:5.
Crossref
Crossref
Yi Zhu, ZhiHeng Chen, HongGang Jiang & BoHao Lu. (2019) The genetic association between EGF A61G polymorphism (rs4444903) and risk of colorectal cancer. Medicine 98:2, pages e14007.
Crossref
Crossref
Resul KAHRAMAN, Elif Sinem İPLİK, Turan ÇALHAN, Abdurrahman ŞAHİN & Bedia ÇAKMAKOĞLU. (2018) Assessment of the role of EGF +61A/G and EGFR R497K polymorphism in patients with inflammatory bowel disease: A case-control studyİnflamatuar bağırsak hastalığında EGF +61A/G ve EGFR R497K polimorfizm rolünün değerlendirilmesi: Bir olgu-kontrol çalışması. Archives of Clinical and Experimental Medicine 3:2, pages 79-83.
Crossref
Crossref
XIAN-FENG SHEN, XIAN-TAO ZENG, ZHI-YUAN JIAN, MENG ZHOU, PING ZHOU & MIN ZHANG. (2015) Quantitative assessment of the effect of epidermal growth factor 61A/G polymorphism on the risk of hepatocellular carcinoma. Oncology Letters 10:5, pages 3199-3205.
Crossref
Crossref
Ying-Hsia Shih, Cheng-Liang Peng, Shin-Yu Lee, Ping-Fang Chiang, Cheng-Jung Yao, Wuu-Jyh Lin, Tsai-Yueh Luo & Ming-Jium Shieh. (2015) 111In-cetuximab as a diagnostic agent by accessible epidermal growth factor (EGF) receptor targeting in human metastatic colorectal carcinoma. Oncotarget 6:18, pages 16601-16610.
Crossref
Crossref
Elena De Mattia, Erika Cecchin & Giuseppe Toffoli. (2015) Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy. Drug Resistance Updates 20, pages 39-70.
Crossref
Crossref
Silvia Mahmood, Monika Sivoňová, Tatiana Matáková, Dusan Dobrota, Ladislava Wsólová, Anton Dzian & Dusan Mištuna. (2014) Association of EGF and p53 gene polymorphisms and colorectal cancer risk in the Slovak population. Open Medicine 9:3, pages 405-416.
Crossref
Crossref
Yingqun Tao & Guobiao Liang. (2013) Quantitative assessment of the association between +61A>G polymorphism of epidermal growth factor gene and susceptibility to glioma. Tumor Biology 35:1, pages 369-377.
Crossref
Crossref
VAHID CHALESHI, MAHDI MONTAZER HAGHIGHI, SANAZ SAVABKAR, NEDA ZALI, MOHSEN VAHEDI, MAHSA KHANYAGHMA, GHOLAM REZA JAVADI, HAMID ASADZADE & MOHAMMAD REZA ZALI. (2013) Correlation between the EGF gene intronic polymorphism, rs2298979, and colorectal cancer. Oncology Letters 6:4, pages 1079-1083.
Crossref
Crossref
Ying Piao, Zhaozhe Liu, Zhenyu Ding, Long Xu, Fang Guo, Qingqing Sun & Xiaodong Xie. (2013) EGF +61A>G polymorphism and gastrointestinal cancer risk: A HuGE review and meta-analysis. Gene 519:1, pages 26-33.
Crossref
Crossref
Lin LinGuixin LiZhanxue ZhangMing WenWeili XuJianhui CaiBaojun ZhouJin Liu. (2012) Association of Epidermal Growth Factor +61 A/G Polymorphism in Chinese Patients with Colon Cancer. Genetic Testing and Molecular Biomarkers 16:9, pages 1142-1145.
Crossref
Crossref
A. Daraei, R. Salehi, M. Salehi, M. H. Emami, M. Jonghorbani, F. Mohamadhashem & H. Tavakoli. (2011) Effect of rs6983267 polymorphism in the 8q24 region and rs4444903 polymorphism in EGF gene on the risk of sporadic colorectal cancer in Iranian population. Medical Oncology 29:2, pages 1044-1049.
Crossref
Crossref
Laetitia Dahan, Emmanuelle Norguet, Marie-Christine Etienne-Grimaldi, Jean-Louis Formento, Mohamed Gasmi, Isabelle Nanni, Jean Gaudart, Stéphane Garcia, L'Houcine Ouafik, Jean-François Seitz & Gérard Milano. (2011) Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. BMC Cancer 11:1.
Crossref
Crossref
Kefei ChenYongGang WeiHanTeng YangBo Li. (2011) Epidermal Growth Factor +61 G/A Polymorphism and the Risk of Hepatocellular Carcinoma in a Chinese Population. Genetic Testing and Molecular Biomarkers 15:4, pages 251-255.
Crossref
Crossref
. 2011. Growth Factors and Their Receptors in Cell Differentiation, Cancer and Cancer Therapy. Growth Factors and Their Receptors in Cell Differentiation, Cancer and Cancer Therapy
249
347
.
Shujie Wang, Yao Zhao, Zhenchao Ruan, Hongyan Chen, Weiwei Fan, Juxiang Chen, Qihan Wu, Ji Qian, Tianbao Zhang, Yan Huang & Daru Lu. (2010) Association between EGF +61 G/A and glioma risk in a Chinese population. BMC Cancer 10:1.
Crossref
Crossref
Wei Xu, Yan Li, Xueli Wang, Bo Chen, Shan Liu, Yan Wang, Weihong Zhao & Jianqing Wu. (2009) Association between EGF promoter polymorphisms and cancer risk: a meta-analysis. Medical Oncology 27:4, pages 1389-1397.
Crossref
Crossref
G Bao, M Wang, S Guo, Y Han & G Xu. (2010) Association between Epidermal Growth Factor +61 G/A Polymorphism and Glioma Risk in a Chinese Han Population. Journal of International Medical Research 38:5, pages 1645-1652.
Crossref
Crossref
Luciana Oliveira de Almeida, Aline Cadurin Custódio, Marcelo José dos Santos, José R.W. Almeida, Carlos Afonso Clara, Giovanny Rebouças Pinto, Juan A. Rey & Cacilda Casartelli. (2010) The A61 G EGF polymorphism is associated with development of extraaxial nervous system tumors but not with overall survival. Cancer Genetics and Cytogenetics 198:1, pages 15-21.
Crossref
Crossref
K.-L. G. Spindler, R.F. Andersen, L.H. Jensen, J. Ploen & A. Jakobsen. (2010) EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer. Annals of Oncology 21:3, pages 535-539.
Crossref
Crossref
Lin Cui, Xin-Min Pan, Chun-Fen Ma, Jun Shang-Guan, Hai-Bin Yu, Guang-Xue Chen & Jia Wang. (2009) Association Between Epidermal Growth Factor Polymorphism and Esophageal Squamous Cell Carcinoma Susceptibility. Digestive Diseases and Sciences 55:1, pages 40-45.
Crossref
Crossref
Milena Casula, Mauro Alaibac, Maria A Pizzichetta, Riccardo Bono, Paolo A Ascierto, Ignazio Stanganelli, Sergio Canzanella, Grazia Palomba, Edoardo Zattra & Giuseppe Palmieri. (2009) Role of the EGF +61A>G polymorphism in melanoma pathogenesis: an experience on a large series of Italian cases and controls. BMC Dermatology 9:1.
Crossref
Crossref
K. -L. Garm Spindler, N. Pallisgaard, A.A. Rasmussen, J. Lindebjerg, R.F. Andersen, D. Crüger & A. Jakobsen. (2009) The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Annals of Oncology 20:5, pages 879-884.
Crossref
Crossref
John L. Marshall. (2009) Vascular Endothelial Growth Factor Plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism?. Journal of Oncology 2009, pages 1-9.
Crossref
Crossref
Lin-Bo Gao, Ye-Sheng Wei, Bin Zhou, Yan-Yun Wang, Wei-Bo Liang, Cui Li, Yi Li, Peng Bai, Wen-Liang Fang, Hui Xue & Lin Zhang. (2008) No association between epidermal growth factor and epidermal growth factor receptor polymorphisms and nasopharyngeal carcinoma. Cancer Genetics and Cytogenetics 185:2, pages 69-73.
Crossref
Crossref
Philipp C. Manegold, Georg Lurje, Alexandra Pohl, Yan Ning, Wu Zhang & Heinz-Josef Lenz. (2008) Can we predict the response to epidermal growth factor receptor targeted therapy?. Targeted Oncology 3:2, pages 87-99.
Crossref
Crossref